Choosing the best anti-Helicobacter pylori therapy: Effect of antimicrobial resistance

American Journal of Gastroenterology

Volumn 91, Issue 6, 1996, Pages 1072-1076

  Graham, David Y ^a   De Boer, Wink A ^b   Tytgat, Guido N J ^b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BISMUTH; CHLORTETRACYCLINE; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; METRONIDAZOLE; OMEPRAZOLE; OXYTETRACYCLINE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG MIXTURE; GASTROINTESTINAL INFECTION; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; TREATMENT OUTCOME;

EID: 0029949471     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Börsch GM, Graham DY. Helicobacter pylori. In: Collen MJ, Benjamin SB, eds. Pharmacology of peptic ulcer disease. Handbook of experimental pharmacology, vol 99. Berlin: Springer-Verlag, 1991: 107-48.
2. Borody TJ, Cole P, Noonan S, et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust 1989; 151:431-5.
3. Graham DY. A reliable cure for Helicobacter pylori infection? Gut 1995;37:154-6.
4. Graham DY, Klein PD, Evans DG, et al. Simple noninvasive method to test efficacy of drugs in the eradication of Helicobacter pylori infection: The example of combined bismuth subsalicylate and nitrofurantoin. Am J Gastroenterol 1991;86:1158-62.
5. Graham DY, Karttunen TJ, Genta RM. The evaluation of treatment of H. pylori infections: Strategies for the design of clinical trials. Endoscopia Digestiva 1994;6:991-1006.
6. Wilhelmsen I, Weberg R, Berstad K, et al. Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease. Hepatogastroenterology 1994;41: 43-7.
7. Borody TJ, George LL, Brandi S, et al. Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy. Scand J Gastroenterol 1992;27:281-4.
8. de Boer WA, Driessen WM, Potters VP, et al. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol 1994;89:1993-7.
9. Graham DY, Börsch GM. The who's and when's of therapy for Helicobacter pylori. Am J Gastroenterol 1990;85:1552-5.
10. Graham DY, Evans DG. Prevention of diarrhea caused by enterotoxigenic Escherichia coli: Lessons learned with volunteers. Rev Infect Dis 1990;12(suppl)1:S68-72.
11. Al-Assi MT, Ramirez FC, Lew GM, et al. Clarithromycin, tetracycline, and bismuth: A new non-metronidazole therapy for Helicobacter pylori infection. Am J Gastroenterol 1994;89:1203-5.
12. Al-Assi MT, Genta RM, Graham DY. Omeprazole-tetracycline combinations are inadequate as therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1994;8:259-62.
13. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993;88:505-9.
14. Hosking SW, Ling TK, Yung MY, et al. Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. Br Med J 1992;305:502-4.
15. Bell GD, Powell KU, Burridge SM, et al. Helicobacter pylori eradication: Efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med 1993;86:743-50.
16. Hosking SW, Ling TK, Chung SC, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: Randomised controlled trial. Lancet 1994;343:508-10.
17. Archimandritis A, Balatsos V, Delis V, et al. Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine. A 12-month follow-up. J Clin Gastroenterol 1995;20:12-6.
18. Sung JJ, Chung SC, Ling TK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995;332: 139-42.
19. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacler pylori with triple therapy. Gastroenterology 1992;102:493-6.
20. Tucci A, Poli L, Gasperoni S, et al. Evaluation of two therapeutic regimens for the treatment of Helicobacter pylori infection. Ital J Gastroenterol 1994;26:107-10.
21. Xia H, Keane CT, Beattie S, et al. Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori. Antimicrob Agents Chemother 1994;38: 2357-61.
22. George LL, Borody TJ, Andrews P, et al. Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust 1990;153:145-9.
23. Berstad A, Berstad K, Hatlebakk JG, et al. 10 days of triple treatment of Helicobacter pylori infection and peptic ulcer. Status after treatment of 4 weeks and of one year. Tidsskr Nor Laegeforen 1994;114:2477-9.
24. Rautelin H, Seppala K, Renkonen OV, et al. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother 1992;36:163-6.
25. Queiroz DM, Coimbra RS, Mendes EN, et al. Metronidazole-resistant Helicobacter pylori in a developing country. Am J Gastroenterol 1993;88:322-3 (letter).
26. Harries AD, Stewart M, Deegan KM, et al. Helicobacter pylori in Malawi, central Africa. J Infect 1992;24:269-76.
27. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992;11:777-81.
28. Banatvala N, Davies GR, Abdi Y, et al. High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: Relation with previous nitroimidazole exposure and gastroduodenal disease. Gut 1994;35:1562-6.
29. Seppala K, Farkkila M, Nuutinen H, et al. Triple therapy of Helicobacter pylori infection in peptic ulcer. A 12-month follow-up study of 93 patients. Scand J Gastroenterol 1992;27:973-6.
30. Tytgat GN. Review article: Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994;8:359-68.
31. Penston JG. Review article: Helicobacter pylori eradication: Understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994;8:369-89.
32. Noach LA, Langenberg WL, Bertola MA, et al. Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis 1994;26:321-7.
33. Thijs JC, van Zwet AA, Oey HB. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993;28:934-8.
34. Wilhelmsen I, Tangen Haug T, Sipponen P, et al. Helicobacter pylori in functional dyspepsia and normal controls. Scand J Gastroenterol 1994;29:522-7.
35. Wilhelmsen I, Berstad A. Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter pylori. Scand J Gastroenterol 1994;29:874-9.
36. Sung JJ, Leung VK, Chung SC, et al. Triple therapy with sucralfate, tetracycline, and metronidazole for Helicobacter pylori-associated duodenal ulcers. Am J Gastroenterol 1995;90:1424-7.
37. Cederbrant G, Kahlmeter G, Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother 1992;29:115-20.
38. Versalovic J, Shortridge D, Kibsten K, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996;40:477-480.
39. Goldman RC, Zakula D, Ramm R, et al. Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. Antimicrob Agents Chemother 1994;38:1496-500.
40. de Boer WA, Tytgat GN. 90% cure: Which anti-Helicobacter therapy can achieve this treatment goal? Am J Gastroenterol 1995;90: 1381-2.
41. de Boer W, Driessen W, Jansz A, et al. Effect of acid suppression on efficacy of treatment for Helicobacter pylon infection. Lancet 1995; 345:817-20.
42. Malanoski GJ, Eliopoulos GM, Ferraro MJ, et al. Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microbiol Infect Dis 1993;12:131-3.
43. Debets-Ossenkopp YJ, Namavar F, MacLaren DM. Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents. Eur J Clin Microbiol Infect Dis 1995;14:353-5.
44. Bazzoli F, Zagari RM, Fossi S, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;6:773-7.
45. Labenz J, Peitz U, Tillenburg B, et al. Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori. Leber Magen Darm 1995;25:122, 125-7.
46. Yousfi MM, el-Zimaity HM, Al-Assi MT, et al. Metronidazole, omeprazole and clarithromycin: An effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1995;9:209-12.